
Anondita Medicare Secures First Export Order of Rs. 43.14 Crore under South African Government Tender
Anondita Medicare Limited announced its inclusion as a manufacturer/supplier in a Government of South Africa tender, marking the company's commencement of international supplies. The approval covers the supply and delivery of condoms under a tender agreement spanning from November 1, 2025, to October 31, 2030.The process followed successful due diligence and audit conducted by the South African Bureau of Standards (SABS).
The Government of South Africa awarded the overall tender to M/s. Supra Healthcare Johannesburg (Pty) Ltd., a local South African entity. Following this award, the local entity placed initial purchase orders with Anondita Medicare Limited, resulting in the company receiving its first export purchase order.
This initial order, received on May 29, 2026, aggregates to approximately Rs. 43.14 Crore (Rupees Forty-Three Crore Fourteen Lakh Only) for the supply and delivery of male condoms. The order comprises supplies equivalent to 50 containers (40-foot containers) and is scheduled for execution by September 30, 2026.
The company stated that this order is expected to strengthen Anondita Medicare Limited's export business and enhance its presence in international institutional markets.
Order Details Summary
| Detail | Description |
|---|---|
| Awarding Entity | Supra Healthcare Johannesburg (Pty) Ltd. |
| Nature of Goods | Male Condoms |
| Transaction Type | Supply of Condoms |
| Market | International |
| Financial Consideration | Rs. 43.14 Crore (approx.) |
| Logistics | 50 containers (40-foot containers) |
| Execution Timeline | Order to be executed by September 30, 2026 |
| Tender Period | November 1, 2025, to October 31, 2030 |
| Foreign Interest | International Entity |
ANONDITA Stock Price Movement
Anondita Medicare Limited shares rallied on Friday, climbing 5.30% to settle at ₹1061.95. The stock’s significant upward movement was backed by a solid volume of 25,200 shares traded during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.